Overview
Pharmaceutical

Renascience Inc.

Renascience is a Japanese biotech venture company engaged in the research and development of multiple modalities — including small molecule drugs, medical devices, and AI-powered software as medical devices (SaMD) — targeting aging-related diseases (NCDs such as cancer, diabetes, respiratory, and cardiovascular diseases) as well as women's and pediatric health conditions. The company operates an asset-light, open-innovation model, leveraging physician-scientists at partner universities (including Tohoku University and Hiroshima University) to conduct physician-initiated clinical trials from basic research through Phase III studies. Its business model focuses on advancing pipeline assets to late-stage development before out-licensing to major pharmaceutical companies, with the aim of generating significant licensing revenues.

Market Cap
¥13.7B
US$87.2M
EV
¥10.5B
US$66.8M
Stock¥993▲+0.30%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
4.2
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-70.1%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Aug 17, 26Q1 FY2027/03 earnings announced
MC → EV Bridge
13.7BUS$87.2MMarket Cap0.00BUS$0.00M+ Debt3.20BUS$20.4M− Cash0.00BUS$0.00M− Inv. Sec.10.5BUS$66.8MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.14US$0.89M'22/30.10US$0.64M'23/30.19US$1.24M'24/30.13US$0.84M'25/30.07US$0.43M'26/3
EBITDA 5Y (¥B)
-0.21-US$1.32M'22/3-0.33-US$2.11M'23/3-0.25-US$1.60M'24/3-0.18-US$1.13M'25/3-0.36-US$2.27M'26/3
Net Income 5Y (¥B)
-0.25-US$1.62M'22/3-0.34-US$2.14M'23/3-0.26-US$1.65M'24/30.11US$0.72M'25/3-0.30-US$1.92M'26/3
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
2.39US$15.2M0.20US$1.27M'22/32.21US$14.1M0.31US$1.97M'23/32.03US$12.9M0.36US$2.27M'24/31.80US$11.5M'25/33.40US$21.7M'26/3
Shareholders
Top 10 hold 53.8%
1
SMBC Trust Bank Ltd. (Trustee of Specified Securities Trust)
31.65%
2
Toshio MIYATA
10.68%
3
Ueda Yagi Tanshi Co., Ltd.
2.18%
4
BNYM SA/NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE (Standing Proxy: MUFG Bank, Ltd.)
2.00%
5
BOFAS INC SEGREGATION ACCOUNT (Standing Proxy: BofA Securities Japan Co., Ltd.)
1.91%
6
Rakuten Securities, Inc. (Joint Account)
1.38%
7
Hiroaki HAYASHIDA
1.26%
8
Daiichi Realtor Co., Ltd.
1.14%
9
SBI SECURITIES Co., Ltd.
1.09%
10
Shinichi IIDA
0.47%
Management
5 officers
Toshio MIYATA
Director, Chairman and President
Apr 1990 Research Fellow, Japan Society for the Promotion of Science Jun 1991 Assistant Professor, Department of Immunodeficiency Research, Research Institute for Microbial Diseases, Osaka University May 1994 Lecturer, Department of Internal Medicine, Branch Hospital, Nagoya University School of Medicine Mar 1997 Lecturer, Department of Molecular Pathophysiology and Internal Medicine, Institute of Medical Science, Tokai University Apr 1999 Associate Professor, Department of Molecular Pathophysiology and Internal Medicine, Institute of Medical Science, Tokai University Apr 2003 Professor, Institute of Medical Science, Tokai University Apr 2005 Professor, Department of Nephrology and Metabolic Medicine, School of Medicine, Tokai University; Deputy Director, Institute of Medical Science Apr 2006 Director, Institute of Medical Science, Tokai University Dec 2007 Professor, Department of Molecular Pathophysiology and Therapeutics, Center for Advanced Biomedical Sciences, Graduate School of Medicine, Tohoku University Apr 2008 Assistant to the Dean, Graduate School of Medicine, Tohoku University Jan 2010 Director, Center for Advanced Biomedical Sciences, Graduate School of Medicine, Tohoku University Oct 2017 Vice President (Research and Industry-Academia Collaboration), Tohoku University Apr 2018 Outside Director, the Company Apr 2019 Vice President (Interdisciplinary Research), Tohoku University Apr 2020 Chairman of the Board, the Company Apr 2023 Special Assistant to the Dean (Research and Industry-Academia Collaboration), Graduate School of Medicine, Tohoku University (current) Apr 2024 Vice President (Collaborative Research), Tohoku University (current) Apr 2024 Program Supervisor, Smart Bio Drug Discovery Research Support Program, Japan Agency for Medical Research and Development (current) Jun 2025 Representative Director, President and Chairman, the Company (current) Apr 2026 Research Professor and Special Assistant to the Dean (Research and Industry-Academia Collaboration), Graduate School of Medicine, Tohoku University (current)
1961-02-08
Mitsuaki KAMADA
Director and Vice President
Apr 1986 Joined Ministry of Health and Welfare Jul 1993 Assistant Director, Economic Affairs Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare May 1994 Head of Pharmaceuticals Department, JETRO New York Center Aug 1999 Liaison Coordinator for the Diet, General Affairs Division, Minister's Secretariat, Ministry of Health and Welfare Aug 2007 Director, Public Relations Office, General Affairs Division, Minister's Secretariat, Ministry of Health and Welfare Jul 2009 Councillor, Cabinet Secretariat (Councillors' Office on Cabinet Affairs, Prime Minister's Official Residence) Jul 2011 Director, Economic Affairs Division, Medical Affairs Bureau, Ministry of Health, Labour and Welfare Jul 2013 Director, General Affairs Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Oct 2015 Senior Coordinator, Pharmaceuticals and Medical Devices Agency Jun 2016 Director General, International Cooperation Bureau, National Center for Global Health and Medicine Jul 2017 Senior Councillor, Cabinet Secretariat (Deputy Director, Health and Medical Strategy Office) Jul 2018 Director-General, Tohoku Bureau of Health and Welfare, Ministry of Health, Labour and Welfare Mar 2020 Director-General, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare Nov 2022 Advisor, Public Corporation Division, Dai-ichi Life Insurance Company, Limited (current) Nov 2022 Specially Appointed Professor, Tohoku University Jun 2025 Director and Vice President, the Company (current)
1962-11-30
Hiroaki NOSHIRO
Director (Full-time Audit and Supervisory Committee Member) (Note 1)
Apr 1984 Joined Development Bank of Japan (formerly Japan Development Bank) Sep 2010 General Manager, Legal and Compliance Department, Development Bank of Japan Jun 2012 Managing Director and General Manager, General Affairs Department, Tokyo Bay Aqua-Line Co., Ltd. Jun 2023 Senior Advisor, Development Bank of Japan Jun 2023 Audit & Supervisory Board Member, DBJ Business Support Co., Ltd. Jun 2024 Outside Director (Full-time Audit and Supervisory Committee Member), the Company (current)
1959-06-24
Akihiko ITO
Director (Audit and Supervisory Committee Member) (Note 1)
Apr 1982 Joined The Long-Term Credit Bank of Japan, Ltd. Nov 1999 Joined Central Japan Railway Company Jul 2004 General Manager, Shizuoka Branch Administration Department, Central Japan Railway Company May 2006 Deputy General Manager, Personnel Department, Central Japan Railway Company Jun 2008 General Manager, Secretariat, Central Japan Railway Company Jul 2012 Deputy General Manager, Business Promotion Headquarters, Central Japan Railway Company Jun 2014 Executive Officer and General Manager, Property Management Department, Central Japan Railway Company Jun 2016 Executive Officer and General Manager, General Affairs Department, Central Japan Railway Company Jun 2018 Director, Managing Executive Officer and General Manager, Business Promotion Headquarters, Central Japan Railway Company Jun 2020 Senior Managing Executive Officer (in charge of Secretariat, Audit, Public Relations, General Affairs and Property Management Departments), Central Japan Railway Company Jun 2022 President and Representative Director, JR Central Hotels Co., Ltd. (current) Jun 2025 Outside Director (Audit and Supervisory Committee Member), the Company (current)
1959-10-07
Satoshi KITAURA
Director (Audit and Supervisory Committee Member) (Note 1)
Mar 1979 Joined The 77 Bank, Ltd. Jun 2004 General Manager, Corporate Sales Department, The 77 Bank, Ltd. Jun 2008 Full-time Audit & Supervisory Board Member, The 77 Bank, Ltd. Jun 2012 Managing Director, Miyagi Shoji Co., Ltd. Jul 2016 President and Director, 77 Capital Co., Ltd. Jun 2019 Resigned as President and Director, 77 Capital Co., Ltd. Jun 2025 Outside Director (Audit and Supervisory Committee Member), the Company (current)
1954-04-04
Large Shareholding Reports
Heights Capital Management, Inc.
2026-10-05
6.65%→4.78%
Heights Capital Management, Inc.
2026-10-01
6.65%→6.65%
Heights Capital Management, Inc.
2026-09-29
6.65%→6.65%
Heights Capital Management, Inc.
2026-09-24
8.47%→6.65%
Heights Capital Management, Inc.
2026-05-26
8.47%→8.47%
Heights Capital Management, Inc.
2026-05-15
6.61%→8.47%
Heights Capital Management, Inc.
2026-04-02
5.59%→6.61%
Heights Capital Management, Inc.
2026-03-12
5.59%
Toshio MIYATA
2025-12-19
21.53%→21.07%
Annual report (as of 2026-03-31): 10.68%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-10-05
Large Shareholding Report
EDINET
2026-10-01
Large Shareholding Report
EDINET
2026-09-29
Large Shareholding Report
EDINET
2026-09-24
Large Shareholding Report
TDnet
2026-08-14
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-05-26
Large Shareholding Report
EDINET
2026-05-15
Large Shareholding Report
EDINET
2026-04-02
Large Shareholding Report
EDINET
2026-03-12
Large Shareholding Report
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-12-19
Large Shareholding Report
EDINET
2025-11-12
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINETAmended
2025-09-03
Amended Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-08-13
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-13
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-08
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-28
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-08
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-09
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-30
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-09
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-10
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-30
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-11
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →